2024-02-06T14:41:49-06:00 2023-06-30 930900579 MCDONALD JACOBS PC 121 SW SALMON ST STE 1100 PORTLAND OR 97204 990 2022-07-01 930571472 NATIONAL PSORIASIS FOUNDATION NATI 5032447404 1800 DIAGONAL ROAD 360 ALEXANDRIA VA 22314 RONALD GOLDSMAN CHIEF FINANCIAL OFFICER 5032447404 2024-02-02 1 RONALD GOLDSMAN 999009999 0 SANG AHN P00540880 5032270581 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z X LEAH MCCORMICK HOWARD 1800 DIAGONAL ROAD 360 ALEXANDRIA VA 22314 15166355 0 X WWW.PSORIASIS.ORG X 1968 OR TO DRIVE EFFORTS TO CURE PSORIATIC DISEASE AND IMPROVE THE LIVES OF THOSE AFFECTED. 16 16 74 778 1080905 279276 11642853 9711727 1766970 2024319 303148 169130 -322618 -313737 13390353 11591439 3215178 3419296 0 0 5787201 6451132 203911 65763 1461846 3331820 3827201 12538110 13763392 852243 -2171953 13977875 13817026 3425275 4798376 10552600 9018650 X THE NATIONAL PSORIASIS FOUNDATION PROVIDES PEOPLE WITH PSORIASIS AND PSORIATIC ARTHRITIS THE SERVICES THEY NEED TO BEST MANAGE THEIR CONDITION, WHILE PROMOTING RESEARCH TO FIND A CURE. 0 0 4438880 3419296 600 RESEARCHNPF CONTINUED TO LEAD COLLABORATIVE, TRANSFORMATIONAL RESEARCH BY ENSURING THAT FUNDING EXTRAMURAL RESEARCH REMINED A PRIORITY. IN FY 2023, NPF INVESTED OVER $3.4M IN RESEARCH GRANTS AND FELLOWSHIP AWARDS, INCLUDING 9 AWARDS TO RESEARCHERS STUDYING THE PREVENTION, TREATMENT, AND MECHANISMS OF PSA. INTRODUCED IN 2020, THE NPF HAS INVESTED OVER $3M TOWARDS THE PSORIASIS PREVENTION INITIATIVE GRANT, A STUDY AIMED AT PREVENTING THE ONSET ON CARDIOVASCULAR DISEASE IN PEOPLE WITH PSORIATIC DISEASE, AND TO PROVIDE, TIMELY, ADEQUATE TREATMENT FOR THOSE DEEMED TO BE AT HIGH RISK OF DEVELOPING CARDIOVASCULAR DISEASE. IN FY 2023, THE PILOT PHASE OF THE UNIVERSITY OF PENNSYLVANIA-LED STUDY ON CVD CONCLUDED AND PLANNING BEGAN FOR THE LAUNCH OF THE FULL STUDY. THIS UNIQUE, SCALABLE MODEL THAT TESTS CARE COORDINATION ACROSS DERMATOLOGISTS AND PRIMARY CARE PROVIDERS SAW PROMISING EARLY RESULTS IN THE PILOT STUDY AND WILL GROW TO 20 SITES IN FY 2024. OF THE 25% OF PEOPLE IN PHASE ONE WHO WERE IDENTIFIED AS HAVING AS HIGH RISK FOR CARDIOVASCULAR DISEASE, 85% FOLLOWED THROUGH WITH AN APPOINTMENT WITH THEIR HEALTH CARE PROVIDER TO ADDRESS CARDIOVASCULAR DISEASE. THE PSA DIAGNOSTIC TEST GRANT WAS ALSO RENEWED FOR TWO INSTITUTIONS WORKING TO DEVELOP A DIAGNOSTIC TEST FOR PSORIATIC ARTHRITIS (PSA). NPF CONTINUED ITS INVESTMENT IN THE MORE THAN SKIN DEEP MENTAL HEALTH GRANT, WHICH FUNDS RESEARCH AIMED AT ADDRESSING MENTAL HEALTH ISSUES, A MAJOR PSORIATIC DISEASE COMORBIDITY. THE NPF COLLABORATED WITH PUBLIC-PRIVATE PARTNERS IN THE ACCELERATED MEDICINES PARTNERSHIP FOR AUTOIMMUNE AND IMMUNE-MEDIATED DISEASES INITIATIVE, PUBLISHED SEVERAL ABSTRACTS AND PAPERS, AND BROUGHT THE INTERNALLY GENERATED DATA TO THE COMMUNITY. 940744 229999 PROFESSIONAL EDUCATIONNPF CONTINUED TO EXPAND AND STRENGTHEN MEDICAL EDUCATION PROGRAMMING TARGETING HEALTH CARE PROVIDERS AT ALL LEVELS AND STAGES OF CAREER. THE 24TH ANNUAL NPF RESIDENTS' MEETING OFFERED DERMATOLOGY RESIDENTS THE LATEST IN PSORIATIC DISEASE TREATMENT PRESENTED BY EXPERTS IN THE FIELD. NPF LAUNCHED A FIRST OF ITS KIND, MEDICAL SCHOOL CURRICULUM TO HELP STUDENTS GAIN A DEEPER UNDERSTANDING OF PSORIATIC DISEASE. THROUGH ITS DEDICATION TO EDUCATING HEALTH CARE PROVIDERS ON PSORIATIC DISEASE AND ITS RELATED DISEASES, NPF HAS EARNED ACCREDITATION AS A PROVIDER OF CONTINUING MEDICAL EDUCATION. IT'S PART OF OUR EFFORTS TO ENSURE ALL DIFFERENT TYPES OF HEALTH CARE PROVIDERS UNDERSTAND THIS COMPLICATED DISEASE. NPF OFFERS THE PSOUND BYTES CME PODCAST, WEBINARS, AND IN-PERSON CLASSES AND SEMINARS FOR A WIDE RANGE OF AUDIENCES AND PUBLISHES THE JOURNAL OF PSORIASIS AND PSORIATIC ARTHRITIS, A PEER REVIEWED OUTLET FEATURING CME ARTICLES. 1222549 ADVOCACYNPF CONTINUED TO ADVOCATE ON BOTH STEP THERAPY AND COPAY ACCUMULATOR ADJUSTMENT PROGRAMS TO ENSURE PATIENTS HAVE AFFORDABLE ACCESS TO THERAPIES. NPF ALSO LEVERAGED THOUSANDS OF ADVOCATES TO WORK FOR HEALTH INSURANCE COVERAGE IMPROVEMENTS FOR THE MILLIONS OF PEOPLE LIVING WITH PSORIATIC DISEASE, WHILE ALSO WORKING TO IMPROVE THE SAFETY AND AFFORDABILITY OF PSORIASIS AND PSA TREATMENTS AND INCREASING FEDERAL SUPPORT FOR PSORIATIC DISEASE RESEARCH. 4015234 713043 EDUCATION, OUTREACH, AND PATIENT SERVICESNPF CONTINUED EXECUTING ON A 3-YEAR GRANT FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION CHRONIC DISEASE EDUCATION AND AWARENESS (CDEA) PROGRAM TOTALING NEARLY $1 MILLION TO RAISE AWARENESS ABOUT PSORIASIS AS AN IMMUNE-MEDIATED, SYSTEMIC INFLAMMATORY DISEASE AMONG THE GENERAL PUBLIC, PUBLIC HEALTH PROFESSIONALS, AND HEALTH CARE PROVIDERS. FUNDING FROM THIS GRANT HAS SUPPORTED NPF CONTINUING MEDICAL EDUCATION (CME) PROGRAMS, PATIENT NAVIGATION CENTER (PNC), AND NPF OUTREACH AND AWARENESS ACTIVITIES.SINCE 2016, NPF'S PATIENT NAVIGATION CENTER HAS SUPPORTED OVER 85,000 PATIENTS AND THEIR CAREGIVERS WITH FREE, PERSONALIZED SUPPORT DESIGNED TO HELP THEM UNDERSTAND PSORIATIC DISEASE AND TREATMENT OPTIONS, NAVIGATE INSURANCE CHALLENGES, AND FIND THE APPROPRIATE HEALTH CARE PROVIDER. NPF ADVANCE MAGAZINE CONTINUED TO PROVIDE THE LATEST INFORMATION, STORIES, AND RESOURCES FIVE TIMES ANNUALLY FOR OVER 25,000 PRINT SUBSCRIBERS AND HUNDREDS OF THOUSANDS OF ONLINE READERS. EACH WEEK, MORE THAN 283,000 PEOPLE RECEIVED ADVANCE WEEKLY, THE OFFICIAL PATIENT-FOCUSED E-NEWSLETTER OF NPF.NPF PROVIDED A COMPREHENSIVE SET OF EDUCATIONAL AND INFORMATIONAL RESOURCES TO OVER 3.6 MILLION VISITORS TO PSORIASIS.ORG AND ASSOCIATED SITES. AS THE TOP SEARCH RESULT FOR SCALP PSORIASIS AND 2ND RESULT FOR PSORIASIS, NPF PROVIDED ACCURATE HEALTH AND MEDICAL INFORMATION TO MILLIONS LIVING WITH PSORIATIC DISEASE. NPF WAS ALSO CITED IN 8.7K OUTSIDE ARTICLES. 4015234 713043 10617407 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 86 0 74 1 1 1 0 0 0 0 1 1 0 0 0 0 0 0 X 16 16 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X X RONALD GOLDSMAN 5032447404 1800 DIAGONAL ROAD 360 ALEXANDRIA VA 22314 RON GRAU CHAIR 1.00 X X 0 0 0 CAROL OSTROW CHAIR-ELECT 1.00 X X 0 0 0 EYAL OFIR VICE CHAIR 1.00 X X 0 0 0 MIKE REFERMAT TREASURER 1.00 X X 0 0 0 RICHARD SEIDEN SECRETARY 1.00 X X 0 0 0 RAYMOND CHIP NEWTON PAST CHAIR 1.00 X 0 0 0 JONATHAN SCOTT DIRECTOR 1.00 X 0 0 0 LARRY GREEN MD DIRECTOR 1.00 X 0 0 0 MARY CARROLL DIRECTOR 1.00 X 0 0 0 MICHAEL GRAFF DIRECTOR 1.00 X 0 0 0 MARK OBERMAN DIRECTOR 1.00 X 0 0 0 JASON LICHTEN MD DIRECTOR 1.00 X 0 0 0 PETE MILLER DIRECTOR 1.00 X 0 0 0 MATTHEW T KISELICA DIRECTOR 1.00 X 0 0 0 APRIL ARMSTRONG MD DIRECTOR 1.00 X 0 0 0 ELAINE HUSNI MD DIRECTOR 1.00 X 0 0 0 LEAH MCCORMICK HOWARD PRESIDENT/CEO 40.00 X 291746 0 15601 RONALD GOLDSMAN CHIEF FINANCIAL OFFICER 40.00 X 142053 0 3477 JENNIFER FAGERSTROM CHIEF REVENUE OFFICER 40.00 X 237132 0 25293 ANDREA CLAY VP OF CORPORATE PARTNERSHIPS 40.00 X 146606 0 8429 KRISTINE BOCKMIER VP OF FIELD DEVELOPMENT & OPERATIONS 40.00 X 146058 0 9627 MICHAEL MACLOED DIRECTOR OF PRINCIPAL GIVING 40.00 X 141110 0 19103 RANDY BERANEK OFFICER THRU DEC 2021 FORMER PRESIDENT/CEO 40.00 X 303058 0 9214 1407763 0 90744 9 1 1 0 CONVERO 835 SHARON DRIVE SUITE 200 CLEVELAND OH 44145 PUBLICATION DEVELOPMENT AND DISTRIBUTION 143636 YOUR PART TIME CONTROLLER LLC 1500 WALNUT SUITE 1200 PHILADELPHIA PA 19102 ACCOUNTING SERVICES 110040 2 101702 30734 1978709 962251 6638331 48752 9711727 ADVERTISING INCOME 541800 1080905 1080905 PRODUCT CERTIFICATION 541900 440789 440789 SCIENTIFIC ADVISORY 541900 229999 229999 PATIENT RECRUITMENT 541900 203918 203918 CONSULTING 541900 68108 68108 600 600 2024319 239338 239338 44962 44962 3145781 3125989 90000 19792 -90000 -70208 -70208 0 1978709 358927 -358927 -358927 228 0 228 228 11591439 943642 1080905 -144835 2422633 2422633 996663 996663 844745 574427 168949 101369 4537816 3085715 907563 544538 136340 92711 27268 16361 514189 349648 102838 61703 418042 284269 83608 50165 114106 77592 22821 13693 65436 44497 13087 7852 229678 229678 65763 65763 29369 29369 817615 654847 54932 107836 422551 413697 8854 893329 598996 52983 241350 342828 233123 68566 41139 705625 497017 17626 190982 46006 31284 9201 5521 TAXES 30584 30584 130074 30610 94744 4720 13763392 10617407 1684139 1461846 X 2356360 2155746 2277242 1788781 512018 703034 6666 4370 127501 152539 593189 207821 508044 385368 8159880 8511304 30164 115884 13977875 13817026 873517 617899 2312500 3845657 160792 168500 78466 166320 3425275 4798376 X 7475871 5506333 3076729 3512317 10552600 9018650 13977875 13817026 -2171953 638003 0 X X 0 1 X 1 0 X 13168307 12708368 11146561 11642853 9711727 58377816 13168307 12708368 11146561 11642853 9711727 58377816 19630337 38747479 124320 216849 164668 214822 284300 1004959 1116715 1291031 1065032 185995 311307 3970080 63352855 4535089 0.61160 0.58390 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 79586 150092 229678 12042499 12272177 763609 190902 0 0 744630 616452 711018 763609 2835709 4253564 448606 199263 153665 229678 1031212 186158 154113 177755 190902 708928 1063392 18486 25348 69888 79586 193308 280000 280000 6868 6868 0 118693 107367 11326 187628 93586 94042 385368 GIFT ANNUITY LIABILITY 23477 DEFERRED COMPENSATION PLAN 38221 OPERATING LEASE 104622 166320 X 12200073 638003 638003 11562070 29369 29369 11591439 13734023 0 13734023 29369 29369 13763392 PART X, LINE 2: THE ORGANIZATION FOLLOWS THE PROVISION OF FASB ASC TOPIC 740 OF ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. MANAGEMENT HAS EVALUATED THE ORGANIZATION'S TAX POSITIONS AND CONCLUDED THAT THERE ARE NO UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS TO COMPLY WITH PROVISIONS OF THIS TOPIC. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANT EXPENSES MORE THAN SKIN DEEP - MENTAL HEALTH & SUMMER STUDENT RESEARCH GRANT 546684 NORTH AMERICA 0 0 GRANT EXPENSES PSA DIAGNOSTIC AWARD 449979 0 0 0 0 0 0 996663 0 996663 SPAIN TRANSLATIONAL RESEARCH GRANT 196725 BANK DRAFT OR COMPUTER CHECK 0 SWEDEN MORE THAN SKIN DEEP - MENTAL HEALTH 149996 BANK DRAFT 0 UK TRANSLATIONAL RESEARCH GRANT 199963 BANK DRAFT OR COMPUTER CHECK 0 CANADA PSA DIAGNOSTIC TEST GRANT 374979 BANK DRAFT 0 CANADA DISCOVERY GRANT 75000 BANK DRAFT 0 5 0 0 0 0 0 0 PART I, LINE 2: GRANT RECIPIENTS WITH MULTI-YEAR AWARDS PROVIDE INTERIM SCIENTIFIC AND PROGRESS REPORTS. ALL GRANT RECIPIENTS PROVIDE A FINAL SCIENTIFIC REPORT AND ACCOUNTING AT THE CONCLUSION OF THE RESEARCH TERM. THE INTERIM AND FINAL REPORTS ARE REVIEWED BY THE RESEARCH DEPARTMENT. PART III ACCOUNTING METHOD: X X X X X X 1 NEXUS DIRECT 780 LYNNHAVEN PARKWAY SUITE 400 VIRGINIA BEACH VA 23452 DIRECT MAIL 0 244871 65763 179108 244871 65763 179108 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY PEER TO PEER (TAKE ACTION/TEAM NPF) 811898 811898 17187 19360 10082 650 34280 COMMIT TO CURE GALA 629539 629539 4231 73894 38483 3134 18965 1 537272 537272 1200 75827 39490 8221 13923 1978709 1978709 22618 169081 88055 12005 67168 358927 -358927 SCHEDULE G, PART II, COLUMN A, EVENT #1 NAME OF EVENT: PEER TO PEER (TAKE ACTION & TEAM NPF) SCHEDULE G, PART II, COLUMN B, EVENT #2 NAME OF EVENT: COMMIT TO CURE GALA SCHEDULE G, PART II, COLUMN C, OTHER EVENTS NAME OF EVENT: OTHER COMMUNITY BUILDING SPECIAL EVENTS 1 BRIGHAM AND WOMEN'S HOSPTAL INC 75 FRANCIS STREET BOSTON MA 02115 900656139 501 (C)(3) 100000 0 MORE THAN SKIN DEEP CASE WESTERN RESERVE UNIVERSITY 1099 EUCLID AVE CLEVELAND OH 441064921 341018992 501 (C)(3) 50000 0 EARLY CAREER RESEARCH GRANT FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH 11400 ROCKVILLE PIKE SUITE 600 NORTH BETHESDA MD 20852 521986675 501 (C)(3) 100000 0 AMP AIM GRANT NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVENUE NEW YORK NY 10016 135562308 501 (C)(3) 399997 0 PSA DIAGNOSTIC TEST GRANT AND BRIDGE GRANT REGENTS OF THE UNIVERSITY OF CALIFORNIA (UNIVERSITY OF CALIFORNIA DAVIS) PO BOX 989062 WEST SACRAMENTO CA 957989062 946036494 501 (C)(3) 150000 0 BRIDGE GRANT AND PSORIATIC DISEASE RESEARCH FELLOWSHIP AWARD REGENTS OF THE UNIVERSITY OF MICHIGAN 1910 TAUBMAN CENTER ANN ARBOR MI 48109 386006309 501 (C)(3) 175000 0 BRIDGE GRANT AND DISCOVERY GRANT AWARD TRUSTEES OF COLUMBIA UNIVERSITY OF THE CITY OF NEW YORK 154 HAVEN AVE 2ND FLOOR NEW YORK NY 10032 135598093 501 (C)(3) 75000 0 DISCOVERY GRANT AWARD TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA PO BOX 785541 PHILADELPHIA PA 19178 231352685 501 (C)(3) 867993 0 PPI AWARD AND PSORIATIC DISEASE RESEARCH FELLOWSHIP AWARD UNIVERSITY OF ROCHESTER 500 ROSS ST 154-0455 ROCHESTER NY 14642 160743209 501 (C)(3) 200000 0 TRANSLATIONAL RESEARCH GRANT UNIVERSITY OF SOUTHERN CALIFORNIA 3500 S FIGUEROA ST STE 102 LOS ANGELES CA 900898001 951642394 501 (C)(3) 50000 0 PSORIATIC DISEASE RESEARCH FELLOWSHIP AWARD UNIVERSITY OF TEXAS AT DALLAS 800 W CAMPBELL ROAD RICHARDSON TX 75080 750926755 501 (C)(3) 75000 0 DISCOVERY GRANT AWARD VANDERBILT UNIVERSITY MEDICAL CENTER 1211 MEDICAL CENTER DR NASHVILLE TN 37232 352528741 501 (C)(3) 175000 0 TRANSLATIONAL RESEARCH GRANT AND ISCOVERY GRANT AWARD 12 PART I, LINE 2: GRANT RECIPIENTS WITH MULTI-YEAR AWARDS PROVIDE INTERIM SCIENTIFIC AND FISCAL PROGRESS REPORTS. ALL GRANT RECIPIENTS PROVIDE A FINAL SCIENTIFIC REPORT AND ACCOUNTING AT THE CONCLUSION OF THE RESEARCH TERM. THE INTERIM AND FINAL REPORTS ARE REVIEWED BY THE RESEARCH DEPARTMENT. X X X X 1 1 0 1 0 1 0 1 0 RANDY BERANEK OFFICER THRU DEC 2021 FORMER PRESIDENT/CEO 303058 0 0 0 0 0 0 0 9214 0 312272 0 0 0 LEAH MCCORMICK HOWARD PRESIDENT/CEO 275746 0 16000 0 0 0 12920 0 2681 0 307347 0 0 0 JENNIFER FAGERSTROM CHIEF REVENUE OFFICER 220132 0 17000 0 0 0 11354 0 13939 0 262425 0 0 0 MICHAEL MACLOED DIRECTOR OF PRINCIPAL GIVING 138210 0 2900 0 0 0 6407 0 12696 0 160213 0 0 0 KRISTINE BOCKMIER VP OF FIELD DEVELOPMENT & OPERATIONS 146058 0 0 0 0 0 0 0 9627 0 155685 0 0 0 ANDREA CLAY VP OF CORPORATE PARTNERSHIPS 146606 0 0 0 0 0 7293 0 1136 0 155035 0 0 0 PART I, LINES 4A-B SCHEDULE J, PART I, LINE 4A: RANDY BERANAK RECEIVED A FINAL COMPENSATION PAYMENT OF $303,058 THAT WAS PAID OUT OVER TIME. SCHEDULE J, PART I, LINE 4B: EMPLOYER CONTRIBUTIONS TO 401K: LEAH MCCORMICK HOWARD - $12,920 JENNIFER FAGERSTROM - $11,354 MICHAEL MACLOED - $6,407 ANDREA CLAY - $7,293 PART I, LINE 5 THE EXECUTIVE TEAM PERFORMANCE-BASED BONUS PORTION OF COMPENSATION WAS BASED ON A COMBINATION OF THE EMPLOYEE'S PERFORMANCE AGAINST THEIR INDIVIDUAL OBJECTIVES, THE NPF MEETING ITS ANNUAL REVENUE AND NET INCOME TARGETS. THE FOUNDATION ACKNOWLEDGES ALL OF ITS OTHER EMPLOYEES THROUGH ANNUAL LUMP-SUM INCENTIVE AWARDS BASED ON MEETING INDIVIDUAL OBJECTIVES AND THE NPF MEETING ITS ANNUAL NET REVENUE AND NET INCOME TARGETS. PART I, LINE 6 THE EXECUTIVE TEAM PERFORMANCE-BASED BONUS PORTION OF COMPENSATION WAS BASED ON A COMBINATION OF THE EMPLOYEE'S PERFORMANCE AGAINST THEIR INDIVIDUAL OBJECTIVES, THE NPF MEETING ITS ANNUAL REVENUE AND NET INCOME TARGETS. THE FOUNDATION ACKNOWLEDGES ALL OF ITS OTHER EMPLOYEES THROUGH ANNUAL LUMP-SUM INCENTIVE AWARDS BASED ON MEETING INDIVIDUAL OBJECTIVES AND THE NPF MEETING ITS ANNUAL NET REVENUE AND NET INCOME TARGETS. PART I, LINE 7 THE EXECUTIVE TEAM PERFORMANCE-BASED BONUS PORTION OF COMPENSATION WAS BASED ON A COMBINATION OF THE EMPLOYEE'S PERFORMANCE AGAINST THEIR INDIVIDUAL OBJECTIVES, THE NPF MEETING ITS ANNUAL REVENUE AND NET INCOME TARGETS. THE FOUNDATION ACKNOWLEDGES ALL OF ITS OTHER EMPLOYEES THROUGH ANNUAL LUMP-SUM INCENTIVE AWARDS BASED ON MEETING INDIVIDUAL OBJECTIVES AND THE NPF MEETING ITS ANNUAL NET REVENUE AND NET INCOME TARGETS. X 6 48752 FMV ON THE DATE RECEIVED 1 0 1 1 PART I, LINE 32B: THE ORGANIZATION ENGAGES WITH OUTSIDE THIRD PARTIES WHEN ACCEPTING REAL ESTATE DONATIONS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY THE AUDIT & GOVERNANCE COMMITTEE AND IS SHARED WITH ALL BOARD MEMBERS PRIOR TO ITS BEING FILED ELECTRONICALLY WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C WE HAVE A CONFLICT OF INTEREST POLICY THAT IS SIGNED BY ALL DIRECTORS ANUALLY. ALL DIRECTORS AND KEY EMPLOYEES REFRAIN FROM VOTING OR COMMENTING ON ANYTHING WHERE THERE COULD BE A CONFLICT. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS ANNUALLY REVIEWS AND APPROVES THE CEO'S COMPENSATION. THE FOUNDATION UTILIZES AN INDEPENDENT COMPENSATION CONSULTANT AND SUBSCRIBES TO A SALARY SURVEY FOR COMPARABLE INFORMATION FOR SALARIES. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. AUDITED FINANCIAL STATEMENTS ARE ALSO DISPLAYED ON THE WEBSITE. FORM 990, PART XII, LINE 2C THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.